Screener
Ligand Pharmaceuticals LGND Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Other non-operating expense, net | 2,682 | 1,372 | 1,507 | (1,129) |
| Total non-operating income (expenses), net | 55,713 | 2,779 | 14,086 | (11,185) |
| Income (loss) before income taxes | 64,304 | 11,223 | 40,045 | (38,957) |
| Income tax (expense) benefit | (15,796) | (6,376) | (4,882) | 1,353 |
| Net income (loss) | $48,508 | $4,847 | $35,163 | $(37,604) |
| Basic net income (loss) per share | $2.42 | $0.25 | $1.76 | $(1.95) |
| Shares used in basic per share calculation | 20,063 | 19,327 | 19,974 | 19,259 |
| Diluted net income (loss) per share | $2.22 | $0.24 | $1.63 | $(1.95) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's income tax?
- Ligand Pharmaceuticals (LGND) reported income tax of $15.8M in Q2 2026.
- How has Ligand Pharmaceuticals's income tax changed year-over-year?
- Ligand Pharmaceuticals's income tax increased by 147.7% year-over-year, from $6.38M to $15.8M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Ligand Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude